References
- Houghton M. A., Weiner A. H., Han J., Kuo G., Choo Q. L. Molecular biology of the hepatitis C viruses: Implication for diagnosis, development and control of viral disease. Hepatol. 1991; 2: 381
- Realdi G., Alberti A., Rugge M., et al. Long-term follow-up of acute and chronic non-A, non-B posttransfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23: 270–275
- Alter H. J. Clinical, virological and epidemiological basis for the treatment of chronic nonA, non-B hepatitis. J. Hepatol. 1990; 11(Suppl 1)S19–25
- Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. VV., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362
- Overby L. R. Hepatitis C: looking at a virus that hasn't been seen. Gut 1993; 34(Suppl 2)S6–9
- Simmonds P., Rose K. A., Graham S., et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J. Clin. Microbiol. 1993; 31(6)1493–1503
- Benvegnù L., Fattovich G., Diodati G., et al. Evidence that concurrent HBV and HCV infection increases the risk of developing HCC in cirrhosis: a prospective study. Cancer 1994, in press
- Locasciulli A., Bacigalupo A., VanLint M. T., et al. Hepatitis C virus (HCV) infection in patients with hematological malignancies. Ital. J. Gastroenterol 1993; 25: 458
- Locasciulli A., Bacigalupo A., VanLint M. T., et al. Hepatitis C virus infection in patients with hematological malignancies treated with chemotherapy or bone marrow transplantation (BMT). Exp. Hematol 1990; 18: 696
- Locasciulli A., Gomati G., Tagger A., et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission. Blood 1991; 78: 1619–1622
- Locasciulli A., Pontisso P., Cavalletto D., et al. Evidence against the role of hepatitis C virus in severe liver damage occurring early in the course of acute leukemia in children. Leuk. Lymphoma 1994; 13: 119–122
- Locasciulli A., Cavalletto D., Pontisso P., et al. Hepatitis C virus serum markers and liver disease in children with leukemia during and after chemotherapy. Blood 1993; 82: 2564–2567
- Gruber A., Norder H., Magnius L., et al. Late seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders. Ann. Oncol. 1993; 4: 229–234
- Brink N. S., Chopra R., Perrons C. J., et al. Acute hepatitis C infection in patients undergoing therapy for haematological malignancies: a clinical and virological study. Br. J. Haematol 1993; 83: 198–503
- Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998–2004
- Locasciulli A., Mieli-Vergani G., Uderzo C., et al. Chronic liver disease in children with leukemia in long-term remission. Cancer 1983; 52: 1080–1087
- Vergani D., Locasciulli A., Masera G., et al. Histological evidence of hepatitis B virus infection with negative serology in children with leukemia who developed chronic liver disease. Lancet 1982; i: 361–364
- Locasciulli A., Alberti A., Barbieri R., et al. Evidence of non-A, non-B hepatitis in children with acute leukemia and chronic liver disease. Am. J. Dis. Child. 1983; 137: 354–356
- Wright T. L. Etiology of Fulminant hepatic failure: is another virus involved?. Gastroenterol 1993; 104: 640–653
- Locasciulli A., Uderzo C., Pirola A., Masera G., Portmann B., Alberti A. Pattern of liver disease following high-dose cytosine arabinoside (HDARAC) therapy in children with acute myeloid leukemia. Leuk. Lymphoma 1990; 2: 229–233
- Locasciulli A., Mura R. M., Fraschini D., et al. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study. Haematologica 1992; 77: 49–53
- Alberti A., Morsica G., Chemello L., et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697–698